These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 25497068

  • 1. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
    Kim MP, Correa AM, Hofstetter W, Mehran R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Erasmus JJ, Swisher SG.
    Ann Thorac Surg; 2015 Feb; 99(2):414-20. PubMed ID: 25497068
    [Abstract] [Full Text] [Related]

  • 2. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 3. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y, Suzuki K, Takamochi K, Matsunaga T, Oh S.
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [Abstract] [Full Text] [Related]

  • 4. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.
    Ghaly G, Rahouma M, Kamel MK, Nasar A, Harrison S, Nguyen AB, Port J, Stiles BM, Altorki NK, Lee PC.
    Ann Thorac Surg; 2017 Oct; 104(4):1153-1158. PubMed ID: 28551047
    [Abstract] [Full Text] [Related]

  • 5. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ, MacRae R, Sirisegaram A, Pantarotto JR.
    Int J Radiat Oncol Biol Phys; 2014 Feb 01; 88(2):312-8. PubMed ID: 24411602
    [Abstract] [Full Text] [Related]

  • 6. Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer.
    Ose N, Sawabata N, Minami M, Inoue M, Shintani Y, Kadota Y, Okumura M.
    Eur J Cardiothorac Surg; 2012 Jul 01; 42(1):89-92. PubMed ID: 22290887
    [Abstract] [Full Text] [Related]

  • 7. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
    Taus Á, Aguiló R, Curull V, Suárez-Piñera M, Rodríguez-Fuster A, Rodríguez de Dios N, Pijuan L, Zuccarino F, Vollmer I, Sánchez-Font A, Belda-Sanchis J, Arriola E.
    Arch Bronconeumol; 2014 Mar 01; 50(3):99-104. PubMed ID: 24360985
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan 01; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 9. Non-small cell lung cancer: prognostic importance of positive FDG PET findings in the mediastinum for patients with N0-N1 disease at pathologic analysis.
    Xie L, Saynak M, Veeramachaneni NK, Fried DV, Jagtap MR, Chiu WK, Higginson DS, Lawrence MV, Khandani AH, Qaqish BF, Chen RC, Marks LB.
    Radiology; 2011 Oct 01; 261(1):226-34. PubMed ID: 21813742
    [Abstract] [Full Text] [Related]

  • 10. Limitations of PET/CT in the Detection of Occult N1 Metastasis in Clinical Stage I(T1-2aN0) Non-Small Cell Lung Cancer for Staging Prior to Stereotactic Body Radiotherapy.
    Akthar AS, Ferguson MK, Koshy M, Vigneswaran WT, Malik R.
    Technol Cancer Res Treat; 2017 Feb 01; 16(1):15-21. PubMed ID: 26792491
    [Abstract] [Full Text] [Related]

  • 11. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr 01; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
    Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, Poncelet AJ.
    Eur J Cardiothorac Surg; 2008 May 01; 33(5):819-23. PubMed ID: 18374589
    [Abstract] [Full Text] [Related]

  • 13. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
    Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Scheiderbauer J, Budach W, Kotzerke J, Bares R.
    Eur J Nucl Med Mol Imaging; 2007 Jan 01; 34(1):54-9. PubMed ID: 16896660
    [Abstract] [Full Text] [Related]

  • 14. Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients.
    Kim SJ, Kim YK, Kim IJ, Kim YD, Lee MK.
    Clin Nucl Med; 2011 Jun 01; 36(6):434-9. PubMed ID: 21552019
    [Abstract] [Full Text] [Related]

  • 15. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C, Sonmezoglu K, Toker A, Yilmazbayhan D, Dilege S, Halac M, Erelel M, Ece T, Mudun A.
    Clin Nucl Med; 2007 Aug 01; 32(8):607-12. PubMed ID: 17667432
    [Abstract] [Full Text] [Related]

  • 16. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.
    Li X, Zhang H, Xing L, Ma H, Xie P, Zhang L, Xu X, Yue J, Sun X, Hu X, Chen M, Xu W, Chen L, Yu J.
    Radiother Oncol; 2012 Feb 01; 102(2):246-50. PubMed ID: 22100657
    [Abstract] [Full Text] [Related]

  • 17. Predictors of survival and disease-free survival in patients with resected N1 non-small cell lung cancer.
    Cerfolio RJ, Bryant AS.
    Ann Thorac Surg; 2007 Jul 01; 84(1):182-8; discussion 189-90. PubMed ID: 17588408
    [Abstract] [Full Text] [Related]

  • 18. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A, Pelosi E, Skanjeti A, Arena V, Errico L, Borasio P, Mancini M, Ardissone F.
    Eur J Cardiothorac Surg; 2009 Sep 01; 36(3):440-5. PubMed ID: 19464906
    [Abstract] [Full Text] [Related]

  • 19. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Gu CS, Kuruvilla MS, Cline KJ, Julian JA, Evans WK, Levine MN.
    J Thorac Oncol; 2011 Aug 01; 6(8):1367-72. PubMed ID: 21587082
    [Abstract] [Full Text] [Related]

  • 20. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT.
    Ann Surg; 2013 Feb 01; 257(2):364-70. PubMed ID: 22968069
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.